Psychotropic dose equivalence in Japan.

作者: Toshiya Inada , Ataru Inagaki

DOI: 10.1111/PCN.12275

关键词: Psychotropic AgentAntiparkinsonian drugsRandomized controlled trialMedical prescriptionEquivalence (measure theory)PsychiatryMedicineTherapeutic equivalencyRacial differencesAntipsychotic

摘要: Psychotropic dose equivalence is an important concept when estimating the approximate psychotropic doses patients receive, and deciding on titration switching from one agent to another. It also useful a research viewpoint defining extracting specific subgroups of subjects. Unification various agents into single standard facilitates easier analytical comparisons. On basis differences in psychopharmacological prescription features, those available their approved doses, racial between Japan other countries, equivalency tables designed specifically for Japanese have been widely used since 1998. Here we introduce for: (i) antipsychotics; (ii) antiparkinsonian agents; (iii) antidepressants; (iv) anxiolytics, sedatives hypnotics Japan. Equivalent therapeutic effects individual compounds were determined principally randomized controlled trials conducted consensus among reported previously by experts. As these are intended merely suggest values, physicians should use them with discretion. Updated information at http://www.jsprs.org/en/equivalence.tables/. [Correction added 8 July 2015, after first online publication: A link updated has added.].

参考文章(17)
Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. American Journal of Psychiatry. ,vol. 144, pp. 1494- 1496 ,(1987) , 10.1176/AJP.144.11.1494
Kalyna Z. Bezchlibnyk-Butler, Gary J. Remington, Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. The Canadian Journal of Psychiatry. ,vol. 39, pp. 74- 84 ,(1994) , 10.1177/070674379403900203
Toshi A Furukawa, Toshiya Inada, Clive E Adams, Hugh McGuire, Ataru Inagaki, Shoko Nozaki, Are the cochrane group registers comprehensive? A case study of Japanese psychiatry trials. BMC Medical Research Methodology. ,vol. 2, pp. 6- 6 ,(2002) , 10.1186/1471-2288-2-6
Michael G. Gelder, Oxford textbook of psychiatry ,(1983)
Maurizio Fava, Katharine G. Davidson, DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION Psychiatric Clinics of North America. ,vol. 19, pp. 179- 200 ,(1996) , 10.1016/S0193-953X(05)70283-5
Jose De Leon, Aruby Odom White, George M. Simpson, Carla Canuso, A Pilot Effort to Determine Benztropine Equivalents of Anticholinergic Medications Psychiatric Services. ,vol. 45, pp. 606- 607 ,(1994) , 10.1176/PS.45.6.606
Verity Humberstone, Amanda Wheeler, Tim Lambert, An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand Australian and New Zealand Journal of Psychiatry. ,vol. 38, pp. 240- 245 ,(2004) , 10.1080/J.1440-1614.2004.01340.X
Pierre V. Tran, Mary Anne Dellva, Gary D. Tollefson, Charles M. Beasley, Janet H. Potvin, Gerilyn M. Kiesler, Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia The Journal of Clinical Psychiatry. ,vol. 58, pp. 205- 211 ,(1997) , 10.4088/JCP.V58N0505
Franca Centorrino, Marion Eakin, Won-Myong Bahk, James P. Kelleher, Jessica Goren, Paola Salvatore, Samy Egli, Ross J. Baldessarini, Inpatient antipsychotic drug use in 1998, 1993, and 1989 American Journal of Psychiatry. ,vol. 159, pp. 1932- 1935 ,(2002) , 10.1176/APPI.AJP.159.11.1932
Scott W. Woods, Chlorpromazine equivalent doses for the newer atypical antipsychotics The Journal of Clinical Psychiatry. ,vol. 64, pp. 663- 667 ,(2003) , 10.4088/JCP.V64N0607